Renishaw plc.   Report issue

For profit Phase 2
Founded: Wotton-under-Edge United Kingdom (1973)

Organization Overview

First Clinical Trial
2017
NCT03295786
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Renishaw plc.

Active Ingredients

Drugs in Phase 2 Trials (1)

Cerebral Dopamine Neurotrophic Factor (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 2)

Movement Disorders (Phase 2)

Nervous System Diseases (Phase 2)

Neurodegenerative Diseases (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1